210 related articles for article (PubMed ID: 25336414)
1. Bacterial endotoxin requirements for dry powder inhalants and their excipients: are they critical quality attributes?
Cundell AM
PDA J Pharm Sci Technol; 2014; 68(5):386-93. PubMed ID: 25336414
[TBL] [Abstract][Full Text] [Related]
2. Quality Assurance and Quality Control, Part 2.
Akers MJ
Int J Pharm Compd; 2015; 19(3):215-21. PubMed ID: 26714362
[TBL] [Abstract][Full Text] [Related]
3. Endotoxin testing in inhalation grade lactose-a useful quality parameter?
Steckel H; Furkert FH
Int J Pharm; 2004 May; 275(1-2):211-5. PubMed ID: 15081151
[TBL] [Abstract][Full Text] [Related]
4. Contamination Control.
Akers MJ
Int J Pharm Compd; 2015; 19(3):232-8. PubMed ID: 26714364
[TBL] [Abstract][Full Text] [Related]
5. Quality Control Testing for Tracking Endotoxin-Producing Gram-Negative Bacteria during the Preparation of Polyvalent Snake Antivenom Immunoglobulin.
Sheraba NS; Diab MR; Yassin AS; Amin MA; Zedan HH
PDA J Pharm Sci Technol; 2015; 69(4):499-510. PubMed ID: 26242786
[TBL] [Abstract][Full Text] [Related]
6. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
Tsong Y; Dong X; Shen M; Lostritto RT
J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
[TBL] [Abstract][Full Text] [Related]
7. From single excipients to dual excipient platforms in dry powder inhaler products.
Shur J; Price R; Lewis D; Young PM; Woollam G; Singh D; Edge S
Int J Pharm; 2016 Dec; 514(2):374-383. PubMed ID: 27262269
[TBL] [Abstract][Full Text] [Related]
8. Gamma sterilization of pharmaceuticals--a review of the irradiation of excipients, active pharmaceutical ingredients, and final drug product formulations.
Hasanain F; Guenther K; Mullett WM; Craven E
PDA J Pharm Sci Technol; 2014; 68(2):113-37. PubMed ID: 24668600
[TBL] [Abstract][Full Text] [Related]
9. Automated endotoxin testing program for high-risk-level compounded sterile preparations at an institutional compounding pharmacy.
Cooper JF; Latta KS; Smith D
Am J Health Syst Pharm; 2010 Feb; 67(4):280-6. PubMed ID: 20133532
[TBL] [Abstract][Full Text] [Related]
10. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
[TBL] [Abstract][Full Text] [Related]
11. A practical discussion of risk management for manufacturing of pharmaceutical products.
Mollah AH; Baseman HS; Long M; Rathore AS
PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348
[TBL] [Abstract][Full Text] [Related]
12. Managing the microbiological quality of pharmaceutical excipients.
Cundell AM
PDA J Pharm Sci Technol; 2005; 59(6):381-95. PubMed ID: 16471425
[TBL] [Abstract][Full Text] [Related]
13. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
[TBL] [Abstract][Full Text] [Related]
14. Excipient variability and its impact on dosage form functionality.
Dave VS; Saoji SD; Raut NA; Haware RV
J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
[TBL] [Abstract][Full Text] [Related]
15. Dry-heat Depyrogenation Ovens for Pharmaceutical Compounding Facilities.
Weller T; Kragseth R; Dullinger R; Illum H; Perry A
Int J Pharm Compd; 2015; 19(3):182-92. PubMed ID: 26714359
[TBL] [Abstract][Full Text] [Related]
16. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
[TBL] [Abstract][Full Text] [Related]
17. Determination of low levels of amorphous content in inhalation grade lactose by moisture sorption isotherms.
Vollenbroek J; Hebbink GA; Ziffels S; Steckel H
Int J Pharm; 2010 Aug; 395(1-2):62-70. PubMed ID: 20493937
[TBL] [Abstract][Full Text] [Related]
18. Orally inhaled drug performance testing for product development, registration, and quality control.
Lastow O; Svensson M
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):401-7. PubMed ID: 25237712
[TBL] [Abstract][Full Text] [Related]
19. A PAT-based qualification of pharmaceutical excipients produced by batch or continuous processing.
Hertrampf A; Müller H; Menezes JC; Herdling T
J Pharm Biomed Anal; 2015 Oct; 114():208-15. PubMed ID: 26072012
[TBL] [Abstract][Full Text] [Related]
20. Best practices for extractables and leachables in orally inhaled and nasal drug products: an overview of the PQRI recommendations.
Norwood DL; Paskiet D; Ruberto M; Feinberg T; Schroeder A; Poochikian G; Wang Q; Deng TJ; DeGrazio F; Munos MK; Nagao LM
Pharm Res; 2008 Apr; 25(4):727-39. PubMed ID: 18183477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
